TP53 and neoplasm: We demonstrate that p53 reactivation limits SCLC disease progression by inducing one of two distinct tumor suppressive programs in individual, clonally-derived neoplasms, with approximately half experiencing a cellular senescence response not associated with a major immune reaction, and the rest undergoing cyclophilin-dependent necrotic cell death.